AstraZeneca's gefurulimab showed clinical benefits and favorable safety in Phase 3 trial for adults with anti-AChR ...

AstraZeneca PLC (NASDAQ:AZN) is one of the Stocks With Huge Catalysts on the Horizon. On July 24, AstraZeneca PLC (NASDAQ:AZN ...

The company didn’t share specific data for the molecule, gefurulimab, but said it hit all endpoints in the Phase III PREVAIL ...

Topline data were announced from a phase 3 trial evaluating gefurulimab in adults with anti-acetylcholine receptor antibody-positive generalised myasthenia gravis.

The pharma sees the drug, gefurulimab, as a more convenient, self-administered alternative to the infused medicines it sells ...

Myasthenia gravis, or MG, is "a chronic autoimmune neuromuscular disorder that causes muscle weakness and fatigue," says Hesterlee. It occurs "when a person’s immune system is essentially ...

If you happen to be on medicine for myasthenia gravis, don't forget it. Any type of light aerobic exercise or anything that you're used to doing, feel free to do.

An optometrist has prescribed prism glasses, which help a little. He’s been wearing an eye patch to drive short distances.

Myasthenia Gravis is further subdivided into the following types based on their signs and symptoms. Generalised Myasthenia Gravis- This occurs when weakness occurs in multiple groups of muscles.

Myasthenia gravis vs. control. Eighty-six per cent (18 of 21) of the control group, and 45 per cent (15 of 33) of the patients with myasthenia gravis had positive DNCB skin tests (Table 3).